Juno said in which could expect approval for its treatment by the end of 2018.
“The acquisition of Juno builds on our shared vision to discover as well as develop transformative medicines for patients with incurable blood cancers,” Celgene CEO Mark Alles said in a statement Monday.
“Juno’s advanced cellular immunotherapy portfolio as well as research capabilities strengthen Celgene’s global leadership in hematology as well as adds brand-new drivers for growth beyond 2020.”
The news comes about a week after the biotech giant announced in which could buy Impact Biomedicines for $7 billion. Both Impact as well as Juno offer drugs in which could boost Celgene inside the market for blood-cancer treatment.
Jefferies analysts called the potential acquisition “smart,” because “the buyout could enable Celgene to integrate Juno’s entire cell therapy platform as well as bring in which all in house.”
David Nierengarten, head of health-care equity research at Wedbush, told CNBC, “Celgene carries a big revenue hole to fill over the next few years” as well as Juno’s treatment could potentially “fill in which gap.”
Celgene has had an estimated $500 million stake in Juno since September, according to a report through Jefferies.
Novartis as well as Gilead Sciences already received the first two approvals of CAR T for some other types of cancer. For one-time treatments, they cost $475,000 as well as $373,000, respectively.
J.P. Morgan Securities is actually acting as financial advisor to Celgene on the transaction, while Morgan Stanley is actually acting as Juno’s advisor.